We reply within one business dayGet my quote
Neuromyelitis optica spectrum disorder (NMOSD): US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Neuromyelitis optica (NMOSD): the short answer
The US FDA has approved four medicines on this page for neuromyelitis optica (NMOSD), each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Enspryng, Uplizna, Soliris and Ultomiris.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is neuromyelitis optica (NMOSD)?
Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the brain and spinal cord. The immune attack causes inflammation of the optic nerve (optic neuritis), with eye pain and vision loss, and of the spinal cord (transverse myelitis).[1]
Spinal cord inflammation can cause weakness, numbness and paralysis of the arms and legs, loss of bladder and bowel control, uncontrollable hiccups and nausea. The relapsing form is most common, with attacks months or years apart and partial recovery in between. About nine times more women than men are affected.[1]
Antibodies against aquaporin-4 (AQP4) are an important marker. All four US medicines on this page are approved for adults with NMOSD who are anti-AQP4 antibody positive. Management of antibody-negative patients remains challenging.[2, 3]
Neuromyelitis optica (NMOSD) in the Gulf
In Kuwait, a study of 42 patients with NMOSD found a female-to-male ratio of 5 to 1, a mean age at onset of 28.9 years, and AQP4 antibodies in 73.8%.[4]
Saudi experts published consensus recommendations on the diagnosis and management of NMOSD in 2022.[2]
US FDA-approved medicines for neuromyelitis optica (NMOSD)
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Enspryng (satralizumab)
FDA-approved for adults with NMOSD who are anti-AQP4 antibody positive. It is an injection under the skin.[3]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman - Uplizna (inebilizumab)
FDA-approved for adults with NMOSD who are anti-AQP4 antibody positive. It is given by intravenous infusion.[7]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman - Soliris (eculizumab)
FDA-approved for adults with NMOSD who are anti-AQP4 antibody positive. It is given by intravenous infusion.[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan - Ultomiris (ravulizumab)
FDA-approved for adults with NMOSD who are anti-AQP4 antibody positive. It is given by intravenous infusion.[9]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for neuromyelitis optica (NMOSD)
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for neuromyelitis optica (NMOSD)?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Enspryng, Uplizna, Soliris and Ultomiris. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Enspryng available in Saudi Arabia or the UAE?
Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Enspryng?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Is NMOSD the same as multiple sclerosis?
No. They can look similar, but NMOSD is a separate autoimmune disease, often marked by AQP4 antibodies. Treatment choices differ, so the correct diagnosis matters.
What if my AQP4 test is negative?
The four US approvals on this page are for antibody-positive adults. The Saudi consensus notes that managing antibody-negative patients remains challenging. Your neurologist will advise.
Sources for the last two answers: [2] [2, 7]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus Genetics (US National Library of Medicine): Neuromyelitis optica
- Shosha et al. Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD). Mult Scler Relat Disord 2022 (PubMed 35908449)
- DailyMed (US National Library of Medicine): Enspryng (satralizumab) US prescribing information, version published 24 June 2026
- Ismail et al. Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. Clin Neurol Neurosurg 2020 (PubMed 32604036)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Uplizna (inebilizumab) US prescribing information, version published 29 September 2026
- DailyMed (US National Library of Medicine): Soliris (eculizumab) US prescribing information, version published 13 July 2026
- DailyMed (US National Library of Medicine): Ultomiris (ravulizumab) US prescribing information, version published 17 November 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Multiple sclerosis
- Myasthenia gravis
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
This page is general health information, not medical advice. It does not replace a consultation with your doctor.